Skip to content

    Strides Pharma Science Limited

    STAR
    Healthcare·31 Oct 2025
    Management Summary

    Strides Pharma delivered a strong Q2 FY26, marked by significant operating leverage and robust profitability growth. While the US market faced intense competition, the company maintained its focus on profitability over top-line growth. Other regulated markets showed strong double-digit growth, contributing to overall performance. The company also demonstrated financial discipline with debt reduction and improved capital efficiency.

    Highlights

    6

    • Q2 FY26 revenue grew by 4.6% year-on-year, demonstrating consistent execution.

    • Gross margins for Q2 FY26 were INR 706 crores, with a percentage of 57.8%, a 500 basis points improvement from Q2 FY25.

    • EBITDA for Q2 FY26 was INR 232 crores, with a 19% margin, marking a 25.4% year-on-year growth.

    • Operational PAT for Q2 FY26 reached INR 140 crores, an 84% year-on-year increase, representing the highest ever quarterly operational PAT.

    • Net debt reduced by INR 73 crores to INR 1,449 crores, improving the Net Debt to EBITDA ratio to 1.65x from 1.9x at March end.

    • ROCE improved to 16% compared to 14.9% in March '25, reflecting enhanced capital efficiency.

    Concerns

    4

    • Intense competition in certain select molecules in the US market, leading to a 2% YoY growth for US revenue.

    • Access markets remain lumpy and challenging due to the donor-funding environment.

    • Adverse forex impact of INR 71 crores on net debt during the quarter.

    • Dropped a few products from commercialization that did not meet profitability thresholds.

    What Changed2

    vs Q3 FY26

    Guidance items9 → 6 (-3)Risks discussed5 → 3 (-2)
    Key financials

    Metrics

    11

    Periods

    3

    Q2

    7
    • Gross Margins
      ₹706 Cr
    • Gross Margin %
      57.8%
    • EBITDA
      ₹232 Cr
      YoY+25.4%
    • EBITDA Margin
      19%
    • Operational PAT
      ₹140 Cr
      YoY+84%

    Q2 end

    3
    • Net Debt
      ₹1,449 Cr
    • Net Debt to EBITDA
      1.65 x
    • ROCE
      16%

    Q2 YoY

    1
    • Revenue Growth
      4.6%

    Segment breakdown

    US Market
    73 Mn Revenue
    Other Regulated Markets (ROW)
    ₹1,030 Cr Revenue14.0% H1 Growth
    Growth Markets
    17 Mn Revenue
    List

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹1,449 crores · 1.6x EBITDA

    M&A

    ANDAs (Intangibles)

    acquisition · closed · Consideration ₹NaN (undisclosed)

    M&A

    OneSource

    acquisition · integrated · Consideration ₹NaN (undisclosed)

    Liquidity

    Liquidity disclosed

    Operational cash of INR 394 crores for H1, with INR 73 crores of free cash used for debt reduction.

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    US Revenue
    $400 million
    		High
    Revenue
    Other Regulated Markets Revenue Growth
    mirror the U.S. market
    		Medium
    R&D
    R&D Spend
    $15 million to $20 million
    		High
    Product Pipeline
    Nasal Spray Filings
    a few more
    		High
    Product Launch
    Nasal Spray Launch Timeline
    18 to 24 months
    		High
    Tax
    Effective Tax Rate (ETR)
    15% to 20%
    		High

    US Revenue Growth towards $400M target

    Next quarter / H2 FY26
    Current$73 million (Q2 FY26), 2% YoY growth
    TargetProgress towards $400 million by FY28

    Why it matters

    Tracking progress on this key long-term revenue target is crucial for validating the company's strategic execution in its largest market.

    And we have given a long-term outlook to the Street in terms of the $400 million by FY '28.

    How to verify

    key_financials.segment_breakdown[name='US Market'].metrics[label='Revenue']

    Risks & concerns

    3
    RiskSeverity

    Intense Competition in US Generics Market

    The US market faces intense competition in certain select molecules, impacting revenue growth despite strategic focus on profitability. — Management acknowledged

    medium

    Lumpy Nature of Access Markets

    Access markets are characterized by lumpiness and challenges in the donor-funding environment, making them opportunistic rather than consistently predictable. — Management acknowledged

    medium

    Adverse Forex Impact on Net Debt

    An adverse forex impact of INR 71 crores affected net debt, though the company still managed to reduce overall net debt. — Management acknowledged

    low

    Q&A highlights

    8

    “So if you really see, we have also specifically said that as far as the U.S. market is concerned, there has been some intense competition in certain select molecules. And if you really see the entire buildup of the U.S. market, we are focused on profitability and we are focused on various other metrics which are outside the we are also focusing on a number of metrics.”

    Clarifies management's strategic choice to prioritize profitability and service levels in the US market, even if it results in flatter revenue growth, contrasting with strong growth in other markets.

    asked by Anand Mundra

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q2 FY26 Performance Driven by Operating Leverage

    Strides Pharma delivered a robust Q2 FY26, showcasing significant operating leverage. Revenue grew by 4.6% year-on-year, which translated into a nearly 3x increase in gross margin growth, a 5x-6x increase in EBITDA growth (25.4% YoY), and an impressive 20x increase in operational PAT growth (84% YoY). The company's gross margin percentage stood at 57.8% (INR 706 crores) and EBITDA margin at 19% (INR 232 crores) for the quarter, reflecting strong execution.

    02

    Strategic Focus on Profitability in US Market Amidst Competition

    Despite intense competition in certain select molecules, the US market contributed $73 million, growing 2% year-on-year. Management reiterated its calibrated approach, prioritizing profitability and service levels over chasing top-line revenue growth. The company has focused on programs beyond the $400 million target and has strategically dropped products that did not meet profitability thresholds, ensuring sustainable value creation in a competitive landscape.

    03

    Double-Digit Growth in Other Regulated Markets and Growth Markets

    The company's 'rest of the world' markets, encompassing other regulated markets and growth markets, demonstrated strong performance, reaching INR 1,030 crores (USD 10.3 billion) for the first time. This segment grew 14% in H1 and 16% year-on-year for other regulated markets, with management expressing confidence in mirroring the US market's scale within the next 2-3 years. Growth markets specifically contributed $17 million, up 7% YoY, indicating broad-based international traction.

    04

    Healthy Capital Allocation and Debt Reduction Initiatives

    Strides invested INR 149 crores in capex during H1 FY26, which included strategic acquisitions of intangibles (ANDAs) worth INR 100 crores for future growth. The company successfully reduced its net debt by INR 73 crores this quarter, bringing the total net debt to INR 1,449 crores, despite an adverse forex impact of INR 71 crores. This led to an improved Net Debt to EBITDA ratio of 1.65x, down from 1.9x at March end, and an increased ROCE of 16%.

    05

    Advancing Product Pipeline with Focus on Nasal Sprays and R&D

    The company continues to invest significantly in its R&D pipeline, with a projected spend of $15-20 million for FY26. A key focus area is Nasal Sprays, with one product already filed and plans to file a few more within the next 12 months, targeting a launch timeline of 18-24 months. This strategic investment in new segments like Control Substances and Beyond Generics is expected to drive future growth and diversify the product portfolio.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.